We are experienced. We are problem solvers.
At Arrivo, we strive to set a new standard in drug development that starts with the selection of drug candidates and runs throughout clinical development. Our approach and decision-making has delivered a history of excellent returns and product successes that makes us the trusted partner for industry and investors.
Working in partnership with investors, innovators, and pharmaceutical companies, Arrivo is always seeking out solutions for unmet medical needs. We strive to be the new standard for strategic asset selection and develop novel products through process that is both highly efficient and thoughtful.
Arrivo has built a portfolio of diverse late-stage drug candidates with the potential to be first-in-class or best-in-class. It is not just the products that are novel. Our entire approach is novel. Our unique form of drug development has resulted in a history of product successes and excellent returns.
The company stands on a solid foundation as our team has an average of more than 25 years of experience in drug development. We are propelled forward by our insatiable curiosity and drive to solve complex problems and help millions of patients globally.
Our model allows the company to look for potential products that offer improvements in patient care across many different therapeutic areas. We can be opportunistic, and not tied to a particular disease or disorder, because we do not have to worry about the product fitting into our commercial infrastructure. Instead, we find the right commercial partner for each individual product. The flexibility has enabled us to build a pipeline of diverse assets with a common theme, all of our programs address unmet medical needs of patients and all have the potential to be first-in-class or best-in-class.